🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 129 (from laksa087)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa129.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://pubmed.ncbi.nlm.nih.gov/38584057/\')), getAhrefsUnparsedNoserviceFromURL(\'https://pubmed.ncbi.nlm.nih.gov/38584057/\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/","crawl_time":1758090746,"first_indexed_time":0,"http_code":200,"src_unparsed":"gov,nih!nlm,ncbi,pubmed,\/38584057\/ s443","src_root_hash":"7295144728021232729","history_drop_reason":null,"meta_title":"Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination","meta_descriptions":["Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate\/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vac …"],"attrs_boilerpipe_text":"\n        Abstract\n        \n       \n      \n      Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate\/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination.\n     \n    Copyright © 2024. Published by Elsevier India Pvt Ltd.\n   \n        Publication types\n       \n                \n                  \n\n\n\n\n\n  Research Support, Non-U.S. Gov't\n\n\n                \n               \n        MeSH terms\n       \n                  \n                    \n\n\n\n\n\n  Adolescent\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Antibodies, Neutralizing\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Antibodies, Viral\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  BNT162 Vaccine* \/ adverse effects\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Child\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Humans\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Vaccination* \/ adverse effects\n\n\n                  \n                 \n                  \n                    \n\n\n\n\n\n  Vaccines, Inactivated* \/ adverse effects\n\n\n                  \n                 \n        Substances\n       \n                \n                  \n\n\n\n\n\n  Antibodies, Neutralizing\n\n\n                \n               \n                \n                  \n\n\n\n\n\n  Antibodies, Viral\n\n\n                \n               \n                \n                  \n\n\n\n\n\n  BNT162 Vaccine\n\n\n                \n               \n                \n                  \n\n\n\n\n\n  sinovac COVID-19 vaccine\n\n\n                \n               \n                \n                  \n\n\n\n\n\n  Vaccines, Inactivated\n\n\n                \n              ","attrs_markdown":"# Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination\nVaccine. 2024 Apr 30;42(12):2951-2954.   doi: 10.1016\/j.vaccine.2024.04.011.   Epub 2024 Apr 6.\n\n### Authors\n[Chia-Yin Chong](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Chong+CY&cauthor_id=38584057)  [1](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-1 \"Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore. Electronic address: Chong.chia.yin@singhealth.com.sg.\") , [Kai-Qian Kam](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kam+KQ&cauthor_id=38584057)  [2](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-2 \"Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore.\") , [Jinyan Zhang](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Zhang+J&cauthor_id=38584057)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-3 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Antonio Bertoletti](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Bertoletti+A&cauthor_id=38584057)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-3 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Smrithi Hariharaputran](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hariharaputran+S&cauthor_id=38584057)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-3 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Rehena Sultana](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sultana+R&cauthor_id=38584057)  [4](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-4 \"Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Rupini Piragasam](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Piragasam+R&cauthor_id=38584057)  [5](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-5 \"Research Centre, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore.\") , [Yun-Yan Mah](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Mah+YY&cauthor_id=38584057)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-3 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Chee-Wah Tan](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Tan+CW&cauthor_id=38584057)  [6](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-6 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Address: 5 Science Drive 2, Block MD4 level 2, Singapore 117545, Republic of Singapore.\") , [Linfa Wang](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Wang+L&cauthor_id=38584057)  [3](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-3 \"Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\") , [Chee-Fu Yung](https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yung+CF&cauthor_id=38584057)  [7](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/#affiliation-7 \"Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore.\")\n\n### Affiliations\n- 1 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \\#17-01 Singapore 308232, Republic of Singapore. Electronic address: Chong.chia.yin@singhealth.com.sg.\n- 2 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \\#17-01 Singapore 308232, Republic of Singapore.\n- 3 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\n- 4 Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.\n- 5 Research Centre, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore.\n- 6 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Address: 5 Science Drive 2, Block MD4 level 2, Singapore 117545, Republic of Singapore.\n- 7 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \\#17-01 Singapore 308232, Republic of Singapore.\n\n- PMID:   [38584057](https:\/\/pubmed.ncbi.nlm.nih.gov\/38584057\/)\n- DOI:   [10\\.1016\/j.vaccine.2024.04.011](https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.011)\n\n## Abstract\nHeterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate\/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination.\n\nCopyright © 2024. Published by Elsevier India Pvt Ltd.\n\n## Publication types\n- Research Support, Non-U.S. Gov't\n\n## MeSH terms\n- Adolescent\n- Antibodies, Neutralizing\n- Antibodies, Viral\n- BNT162 Vaccine\\* \/ adverse effects\n- Child\n- Humans\n- Vaccination\\* \/ adverse effects\n- Vaccines, Inactivated\\* \/ adverse effects\n\n## Substances\n- Antibodies, Neutralizing\n- Antibodies, Viral\n- BNT162 Vaccine\n- sinovac COVID-19 vaccine\n- Vaccines, Inactivated","attrs_readable_markdown":null,"meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

🚫

NOT INDEXABLE

✅

CRAWLED

6 months ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	FAIL	`download_stamp > now() - 6 MONTH`	6.8 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://pubmed.ncbi.nlm.nih.gov/38584057/
Last Crawled	2025-09-17 06:32:26 (6 months ago)
First Indexed	not set
HTTP Status Code	200
Meta Title	Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination
Meta Description	Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vac …
Meta Canonical	null
Boilerpipe Text	Abstract Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination. Copyright © 2024. Published by Elsevier India Pvt Ltd. Publication types Research Support, Non-U.S. Gov't MeSH terms Adolescent Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine* / adverse effects Child Humans Vaccination* / adverse effects Vaccines, Inactivated* / adverse effects Substances Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine sinovac COVID-19 vaccine Vaccines, Inactivated
Markdown	# Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination Vaccine. 2024 Apr 30;42(12):2951-2954. doi: 10.1016/j.vaccine.2024.04.011. Epub 2024 Apr 6. ### Authors [Chia-Yin Chong](https://pubmed.ncbi.nlm.nih.gov/?term=Chong+CY&cauthor_id=38584057) [1](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-1 "Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore. Electronic address: Chong.chia.yin@singhealth.com.sg.") , [Kai-Qian Kam](https://pubmed.ncbi.nlm.nih.gov/?term=Kam+KQ&cauthor_id=38584057) [2](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-2 "Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore.") , [Jinyan Zhang](https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+J&cauthor_id=38584057) [3](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-3 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Antonio Bertoletti](https://pubmed.ncbi.nlm.nih.gov/?term=Bertoletti+A&cauthor_id=38584057) [3](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-3 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Smrithi Hariharaputran](https://pubmed.ncbi.nlm.nih.gov/?term=Hariharaputran+S&cauthor_id=38584057) [3](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-3 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Rehena Sultana](https://pubmed.ncbi.nlm.nih.gov/?term=Sultana+R&cauthor_id=38584057) [4](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-4 "Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Rupini Piragasam](https://pubmed.ncbi.nlm.nih.gov/?term=Piragasam+R&cauthor_id=38584057) [5](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-5 "Research Centre, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore.") , [Yun-Yan Mah](https://pubmed.ncbi.nlm.nih.gov/?term=Mah+YY&cauthor_id=38584057) [3](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-3 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Chee-Wah Tan](https://pubmed.ncbi.nlm.nih.gov/?term=Tan+CW&cauthor_id=38584057) [6](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-6 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Address: 5 Science Drive 2, Block MD4 level 2, Singapore 117545, Republic of Singapore.") , [Linfa Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+L&cauthor_id=38584057) [3](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-3 "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore.") , [Chee-Fu Yung](https://pubmed.ncbi.nlm.nih.gov/?term=Yung+CF&cauthor_id=38584057) [7](https://pubmed.ncbi.nlm.nih.gov/38584057/#affiliation-7 "Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, #17-01 Singapore 308232, Republic of Singapore.") ### Affiliations - 1 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \#17-01 Singapore 308232, Republic of Singapore. Electronic address: Chong.chia.yin@singhealth.com.sg. - 2 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Address: 10 Medical Drive, Singapore 117597, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \#17-01 Singapore 308232, Republic of Singapore. - 3 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore. - 4 Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore. - 5 Research Centre, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore. - 6 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Address: 5 Science Drive 2, Block MD4 level 2, Singapore 117545, Republic of Singapore. - 7 Infectious Diseases, Department of Paediatrics, KK Women's and Children's Hospital, Address: 100 Bukit Timah Road, Singapore 229899, Republic of Singapore; Duke-NUS Medical School, Address: 8 College Road, Singapore 169857, Republic of Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Address: 11 Mandalay Road, \#17-01 Singapore 308232, Republic of Singapore. - PMID: [38584057](https://pubmed.ncbi.nlm.nih.gov/38584057/) - DOI: [10\.1016/j.vaccine.2024.04.011](https://doi.org/10.1016/j.vaccine.2024.04.011) ## Abstract Heterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 followed by 2 Sinovac-CoronaVac vaccines developed T-cell responses against broad peptides including membrane, nucleoprotein 1 and 2 but levels were highest for Spike protein and lasted until day 150 post-vaccination. Copyright © 2024. Published by Elsevier India Pvt Ltd. ## Publication types - Research Support, Non-U.S. Gov't ## MeSH terms - Adolescent - Antibodies, Neutralizing - Antibodies, Viral - BNT162 Vaccine\* / adverse effects - Child - Humans - Vaccination\* / adverse effects - Vaccines, Inactivated\* / adverse effects ## Substances - Antibodies, Neutralizing - Antibodies, Viral - BNT162 Vaccine - sinovac COVID-19 vaccine - Vaccines, Inactivated
Readable Markdown	null
Shard	129 (laksa)
Root Hash	7295144728021232729
Unparsed URL	gov,nih!nlm,ncbi,pubmed,/38584057/ s443